Android app on Google Play

Protalix (PLX) Shares Jump Following FDA Approval of ELELYSO, Co. to Host Call at 8am ET Wednesday

May 1, 2012 6:39 PM EDT Send to a Friend
Get Alerts PFE Hot Sheet
Trade PFE Now!
Join SI Premium – FREE
Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (AMEX: PLX) announced today that the US FDA approved ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

Protalix said it will host a conference call and webcast for Wednesday, May 2, 2012 at 8:00 AM EDT to review the U.S. Food and Drug Administration's approval of ELELYSO™ for the treatment of Type 1 Gaucher disease.




You May Also Be Interested In


Related Categories

Conference Calls, Corporate News, FDA

Add Your Comment